10月9日 - ** Cidara CDTX.O股价盘前上涨3.54%至102美元
** 该公司称，美国食品和药物管理局已授予其实验性药物CD388 "突破性疗法 "称号，该药物旨在预防甲型和乙型流感高危人群中的重症患者。
** 突破性疗法 "标签旨在加快开发和审查治疗严重疾病或未满足医疗需求的药物
** CDTX公司称，中期试验显示CD388有助于预防健康成年人的季节性流感
** CDTX 公司称，CD388 可在不依赖免疫反应的情况下预防流感
** 抗病毒药物针对高危人群，包括老年人、慢性病患者或免疫力低下者
** 截至上一交易日收盘，股价年累计上涨约 266
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.